Investors
News Releases
- November 2, 2023Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
- October 31, 2023Annovis Bio Announces Pricing of $7.5 Million Public Offering
- October 30, 2023Annovis Bio Announces Launch of Proposed Public Offering
- October 30, 2023Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
- October 24, 2023Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
- October 12, 2023Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
- August 15, 2023Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- July 18, 2023Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
- June 27, 2023Annovis Bio Announces the Filing of a Groundbreaking Patent
- June 20, 2023Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top